To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
- to demonstrate the superiority of Trexima (combination of sumatriptan as the succinate
85 mg and naproxen sodium 500 mg) versus placebo in the acute treatment of migraine
- to demonstrate the superiority of Trexima versus the individual components (sumatriptan
as the succinate 85 mg and naproxen sodium 500 mg), and
- to evaluate the safety of the Trexima.